ATE400653T1 - Chimäre rezeptoren und verfahren zur identifizieren verbindungen mit einem aktivität als metabotropischen glutamatrezeptoren sowie verwendung solcher verbindungen in der behandlung von neurologischer erkrankungen und neurologischenstörrungen - Google Patents

Chimäre rezeptoren und verfahren zur identifizieren verbindungen mit einem aktivität als metabotropischen glutamatrezeptoren sowie verwendung solcher verbindungen in der behandlung von neurologischer erkrankungen und neurologischenstörrungen

Info

Publication number
ATE400653T1
ATE400653T1 AT96925537T AT96925537T ATE400653T1 AT E400653 T1 ATE400653 T1 AT E400653T1 AT 96925537 T AT96925537 T AT 96925537T AT 96925537 T AT96925537 T AT 96925537T AT E400653 T1 ATE400653 T1 AT E400653T1
Authority
AT
Austria
Prior art keywords
receptors
compounds
activity
metabotropic glutamate
metabotropic
Prior art date
Application number
AT96925537T
Other languages
English (en)
Inventor
Forrest H Fuller
Karen J Krapcho
Lance G Hammerland
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE400653T1 publication Critical patent/ATE400653T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT96925537T 1995-07-26 1996-07-25 Chimäre rezeptoren und verfahren zur identifizieren verbindungen mit einem aktivität als metabotropischen glutamatrezeptoren sowie verwendung solcher verbindungen in der behandlung von neurologischer erkrankungen und neurologischenstörrungen ATE400653T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US152695P 1995-07-26 1995-07-26

Publications (1)

Publication Number Publication Date
ATE400653T1 true ATE400653T1 (de) 2008-07-15

Family

ID=21696494

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96925537T ATE400653T1 (de) 1995-07-26 1996-07-25 Chimäre rezeptoren und verfahren zur identifizieren verbindungen mit einem aktivität als metabotropischen glutamatrezeptoren sowie verwendung solcher verbindungen in der behandlung von neurologischer erkrankungen und neurologischenstörrungen

Country Status (10)

Country Link
US (3) US5981195A (de)
EP (1) EP0783577B1 (de)
JP (2) JPH10507934A (de)
AT (1) ATE400653T1 (de)
AU (1) AU710128B2 (de)
CA (1) CA2200606A1 (de)
DE (1) DE69637587D1 (de)
ES (1) ES2308779T3 (de)
IL (2) IL120424A0 (de)
WO (1) WO1997005252A2 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10507934A (ja) * 1995-07-26 1998-08-04 エヌピーエス・ファーマシウティカルズ・インコーポレイテッド 代謝指向型グルタミン酸受容体に活性を示す化合物を同定するためのキメラ受容体および方法、ならびに神経学的障害および疾患の治療におけるそのような化合物の使用
AU750179B2 (en) * 1995-07-26 2002-07-11 Astrazeneca Ab Chimeric receptors and methods for identifying compounds active at metabotropic glutamate receptors and the use of such compounds in the treatment of neurological disorders and diseases
US6084084A (en) * 1996-02-21 2000-07-04 Nps Pharmaceuticals, Inc. Human metabotropic glutamate receptor
WO1999021992A2 (en) * 1997-10-23 1999-05-06 Ganimed Pharmaceuticals Gmbh Nucleic acid molecules encoding a glutamate receptor
US7262280B1 (en) 1998-04-03 2007-08-28 Nps Pharmaceuticals, Inc. G-protein fusion receptors and constructs encoding same
CA2325334A1 (en) * 1998-04-03 1999-10-14 Nps Pharmaceuticals, Inc. G-protein fusion receptors and chimeric gabab receptors
US7341730B1 (en) * 1998-07-13 2008-03-11 University Of Southern California Inhibitors of angiogenesis and tumor growth
CN1361768A (zh) 1999-06-02 2002-07-31 Nps药物有限公司 代谢移变的谷氨酸盐受体拮抗剂和它们治疗中枢神经系统疾病的用途
US6534287B1 (en) 1999-10-25 2003-03-18 Nps Pharmaceuticals, Inc. Human metabotropic glutamate receptor
AU782817B2 (en) * 2000-02-04 2005-09-01 Lexicon Pharmaceuticals, Inc. Novel human G protein coupled receptor proteins and polynucleotides encoding the same
AU2001249569B2 (en) * 2000-03-28 2006-05-04 Lexicon Pharmaceuticals, Inc. Novel human 7tm proteins and polynucleotides encoding the same
EP1305341A1 (de) 2000-07-21 2003-05-02 Merck & Co., Inc. Melanin-konzentrierender hormonrezeptor aus dem hund
EP1364003B1 (de) * 2000-10-03 2008-06-18 AstraZeneca AB G-protein fusionsrezeptoren
JP2004537277A (ja) * 2000-12-22 2004-12-16 ワイス 新規グルタミン酸レセプター調節タンパク質および核酸分子およびそれらの使用
US20100248268A1 (en) * 2001-03-27 2010-09-30 Woods Daniel F Methods to utilize invertebrate chemosensory proteins for industrial and commercial uses
US20070003980A1 (en) * 2001-03-27 2007-01-04 Woods Daniel F Efficient methods to isolate effectors of proteins involved in olfactory or chemosensory pathways and efficient methods to use these effectors to alter organism olfaction, chemosensation, or behavior
CA2449011A1 (en) 2001-05-31 2002-12-05 Merck & Co., Inc. Rhesus monkey, dog and ferret melanin-concentrating hormone type 2 receptor
WO2003035873A1 (en) 2001-10-23 2003-05-01 Ajinomoto Co, Inc Novel glutamic acid receptor and utilization thereof
US6908935B2 (en) 2002-05-23 2005-06-21 Amgen Inc. Calcium receptor modulating agents
US7176322B2 (en) 2002-05-23 2007-02-13 Amgen Inc. Calcium receptor modulating agents
EP1578778B1 (de) 2002-07-23 2011-01-26 Ipsen Pharma Ghrelin-analoga
TWI331922B (en) 2002-08-09 2010-10-21 Ipsen Pharma Sas Growth hormone releasing peptides
US20050186658A1 (en) * 2003-10-17 2005-08-25 Nps Pharmaceuticals, Inc. Chimeric metabotropic glutamate receptors and uses thereof
CN105381453B9 (zh) 2005-09-29 2019-01-11 益普生制药股份有限公司 用于刺激胃肠运动性的组合物和方法
TW200916113A (en) 2007-08-08 2009-04-16 Sod Conseils Rech Applic Method for inhibiting inflammation and pro-inflammatory cytokine/chemokine expression using a ghrelin analogue
US10112984B2 (en) * 2011-06-24 2018-10-30 Haagstreit Medtech Ag Light-sensitive chimeric GPCR protein
US10940167B2 (en) 2012-02-10 2021-03-09 Cvdevices, Llc Methods and uses of biological tissues for various stent and other medical applications
US20140228937A1 (en) 2013-02-11 2014-08-14 Joshua Krieger Expandable Support Frame and Medical Device
US11344578B2 (en) 2017-04-19 2022-05-31 Board Of Regents, The University Of Texas System Immune cells expressing engineered antigen receptors
WO2019165121A1 (en) 2018-02-21 2019-08-29 Board Of Regents, The University Of Texas System Methods for activation and expansion of natural killer cells and uses therof
EP4051694B1 (de) 2019-10-31 2025-07-02 Universität Bern Aav-vektor-varianten für die zufuhr von genen ins auge

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4945050A (en) * 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5030576A (en) * 1986-04-30 1991-07-09 Genentech, Inc. Receptors for efficient determination of ligands and their antagonists or agonists
US4859609A (en) * 1986-04-30 1989-08-22 Genentech, Inc. Novel receptors for efficient determination of ligands and their antagonists or agonists
NZ240921A (en) * 1990-12-12 1994-06-27 Zymogenetics Inc G protein coupled glutamate receptor (neurotransmitters), recombinant production
CA2102780C (en) * 1991-05-10 2007-01-09 Alfred P. Spada Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
US6011068A (en) * 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5688938A (en) * 1991-08-23 1997-11-18 The Brigham & Women's Hospital, Inc. Calcium receptor-active molecules
US5858684A (en) * 1991-08-23 1999-01-12 The Brigham And Women's Hospital, Inc. Method of screening calcium receptor-active molecules
US6031003A (en) * 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5763569A (en) * 1991-08-23 1998-06-09 The Brigham And Women's Hospital, Inc Calcium receptor-active molecules
CA2094987A1 (en) * 1992-05-01 1993-11-02 James P. Burnett, Jr. Human glutamate receptor proteins and associated dna compounds
IL105587A0 (en) * 1992-05-08 1993-09-22 Lilly Co Eli Human metabotropic glutamate receptor and related dna compounds
EP0637237B1 (de) * 1993-02-23 2004-05-19 Brigham And Women's Hospital, Inc. Calciumrezeptoraktive moleküle
US5521297A (en) * 1993-06-04 1996-05-28 Salk Institute Biotechnology/Industrial Associates Nucleic acids encoding human metabotropic glutamate receptors
US6228610B1 (en) * 1993-09-20 2001-05-08 Novartis Corporation Human metabotropic glutamate receptor subtypes (hmR4, hmR6, hmR7) and related DNA compounds
EP1203761B1 (de) * 1994-10-21 2005-01-19 Nps Pharmaceuticals, Inc. Kalzium-Rezeptor aktive Verbindungen
TW502026B (en) * 1995-06-20 2002-09-11 Zeneca Ltd Aromatic compounds useful as antagonists of e-type prostaglandins, processes for the preparation thereof, pharmaceutical compositions comprising the compounds, and intermediates
JPH10507934A (ja) * 1995-07-26 1998-08-04 エヌピーエス・ファーマシウティカルズ・インコーポレイテッド 代謝指向型グルタミン酸受容体に活性を示す化合物を同定するためのキメラ受容体および方法、ならびに神経学的障害および疾患の治療におけるそのような化合物の使用
US6084084A (en) * 1996-02-21 2000-07-04 Nps Pharmaceuticals, Inc. Human metabotropic glutamate receptor
US6288610B1 (en) * 1998-03-19 2001-09-11 Fujitsu Limited Method and apparatus for correcting signals, apparatus for compensating for distortion, apparatus for preparing distortion compensating data, and transmitter
JP2004537277A (ja) * 2000-12-22 2004-12-16 ワイス 新規グルタミン酸レセプター調節タンパク質および核酸分子およびそれらの使用
BE1014570A4 (fr) * 2002-01-11 2004-01-13 Sonaca Sa Procede de fabrication d'une structure cannelee et structure obtenue par ce procede.

Also Published As

Publication number Publication date
IL120424A0 (en) 1997-07-13
AU710128B2 (en) 1999-09-16
DE69637587D1 (de) 2008-08-21
CA2200606A1 (en) 1997-02-13
WO1997005252A3 (en) 1997-05-22
EP0783577A1 (de) 1997-07-16
JP2007006893A (ja) 2007-01-18
JPH10507934A (ja) 1998-08-04
IL120424A (en) 2008-12-29
ES2308779T3 (es) 2008-12-01
US20030113873A1 (en) 2003-06-19
US5981195A (en) 1999-11-09
AU6602296A (en) 1997-02-26
EP0783577B1 (de) 2008-07-09
WO1997005252A2 (en) 1997-02-13
US6534289B1 (en) 2003-03-18

Similar Documents

Publication Publication Date Title
DE69637587D1 (de) Chimäre rezeptoren und verfahren zur identifizieren verbindungen mit einem aktivität als metabotropischen glutamatrezeptoren sowie verwendung solcher verbindungen in der behandlung von neurologischer erkrankungen und neurologischenstörrungen
DE69815090D1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
ATE402698T1 (de) Verwendung von ppar-gamma aktivatoren zur behandlung von hautkrankheiten
DE69535498D1 (de) Verfahren zur behandlung vaskulärer kopfschmerzen
ATE58299T1 (de) Geraet zur behandlung neurovegetativer stoerungen.
DE69611251D1 (de) Hydroperoxeicosatetraensäure derivate enthaltende zusammensetzungen und verfahren zur verwendung zur behandlung des trockenen auges
DE69528475D1 (de) Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
DE69632743D1 (de) Verfahren zur regulierung des vagaltonus
DE60027732D1 (de) Verwendung von anti-rubeola antkörpern zur behandlung von symptomen von erkrankungen des zentralen nervensystems
ATE362363T1 (de) Verwendung von tnf-alpha inhibitoren zur behandlung von nervenwurzelschäden
ATE403437T1 (de) Lfa-1 antagonisten und tnf-alpha antagonisten zur behandlung von rheumatoiden arthritis
DE69617235D1 (de) Epoxysteroide aldosteronantagonist und angiotensin ii rezeptor antagonist kombinationstherapie zur behandlung von congestivem herzversagen
DE69616376D1 (de) Verwendung von Tiagabin zur Behandlung von Schlafstörungen
ATE302194T1 (de) Metabotrope glutamatrezeptorantagonisten zur behandlung von krankheiten des zentralen nervensystems
ATE315230T1 (de) Verfahren zum identifizieren von prostaglandin d2 rezeptor modulatoren
DE69634900D1 (de) Proteintyrosine-kinaseinhibitoren zur behandlung der osteoarthritis
DE60023493D1 (de) Verwendung von synthetischen FXR Liganden zur Behandlung von Krankheiten die mit einem gestörten Gleichgewicht des Cholesterin-Spiegels verbunden sind und von Kolonkrebs
ATE321548T1 (de) Verwendung von statin zur behandlung von hauterkrankungen
ATE210447T1 (de) Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen
ATE435026T1 (de) Verfahren zur prävention und behandlung von diabetes mit neurturin
ATE408840T1 (de) Verfahren zur identifizierung von agenzien zur behandlung von anfällen, neurologischen erkrankungen, endokrinopathien und hormonalen erkrankungen
ATE304855T1 (de) Verwendung von olanzapin zur behandlung von mentalen erkrankungen verursacht durch zerebrovaskuläre erkrankungen
ATE368110T1 (de) Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten
ATE484294T1 (de) Anti-interleukin-9 antikörper oder anti- interleukin-9 rezeptor antikörper zur behandlung von bronchialem hyperreaktionsvermögen
ATE239470T1 (de) Melatonin-derivate zur verwendung in der behandlung von desynchronisierungs-erkankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties